Biopharmaceutical CMO Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Process, End User, Stage

Description

The global Biopharmaceutical CMO Market is projected to grow from $18.7 billion in 2025 to $81.4 billion by 2035, at a compound annual growth rate (CAGR) of 15.8%. The Biopharmaceutical CMO Market is moderately consolidated, with leading global contract manufacturing organizations expanding biologics production capacity, advanced manufacturing technologies, and end-to-end development services to meet rising outsourcing demand. Mammalian cell culture remains the dominant manufacturing platform, supported by increasing production of monoclonal antibodies, recombinant proteins, and next-generation biologics, while cell and gene therapy manufacturing is emerging as a high-growth area. Competition is centered on capacity expansion, single-use bioprocessing, continuous manufacturing, and integrated CDMO capabilities. For instance, in January 2025, Samsung Biologics announced at the 2025 J.P. Morgan Healthcare Conference that it would open Plant 5, expand Bio Campus II, and launch dedicated antibody-drug conjugate (ADC) manufacturing services to strengthen its global CDMO capabilities and meet growing biopharmaceutical outsourcing demand.

Based on Type, the Mammalian segment dominated the Biopharmaceutical CMO Market in 2025 due to its extensive use in the production of complex biologics, particularly monoclonal antibodies, recombinant proteins, and advanced therapeutic biologics. Mammalian cell expression systems, especially Chinese Hamster Ovary (CHO) cells, provide superior protein folding, post-translational modifications, and glycosylation patterns essential for producing high-quality biopharmaceuticals. The increasing commercialization of biologics, expanding biosimilar manufacturing, and growing outsourcing of large-scale biomanufacturing activities have further strengthened demand for mammalian-based contract manufacturing. Continuous investments in high-yield cell line development, bioprocess optimization, and large-scale production capacity continue to reinforce the segment's leading market position.

Market Segmentation
Type	Mammalian, Microbial, Plant, Yeast, Insect, Others
Product	Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell Therapy, Gene Therapy, Others
Services	Process Development, Analytical and QC Studies, Packaging, Fill & Finish Operations, Others
Technology	Single-Use Technology, Continuous Processing, Upstream Processing, Downstream Processing, Others
Application	Oncology, Cardiovascular Diseases, Neurology, Infectious Diseases, Immunology, Others
Process	Upstream, Downstream, Others
End User	Pharmaceutical Companies, Biotechnology Companies, Research Organizations, Others
Stage	Preclinical, Clinical, Commercial, Others

Based on Product, the Cell Therapy segment is projected to register the fastest growth during the forecast period due to the rapid expansion of personalized medicine, increasing approvals of advanced therapy medicinal products (ATMPs), and rising investments in regenerative medicine and immunotherapy. Growing demand for autologous and allogeneic cell therapies, particularly for oncology and rare diseases, is driving pharmaceutical and biotechnology companies to outsource specialized manufacturing to experienced CMOs. Increasing adoption of automated manufacturing platforms, stringent regulatory requirements, and the need for highly controlled production environments are accelerating outsourcing activities. Expanding clinical pipelines and commercialization of next-generation cell therapies are expected to further drive the segment's robust growth.

Geographical Overview

North America dominated the Biopharmaceutical CMO Market in 2025, supported by its well-established biopharmaceutical industry, strong presence of global CDMOs and biotechnology companies, and significant investments in biologics, cell and gene therapies, and advanced manufacturing technologies. The United States leads the regional market owing to its extensive biologics pipeline, favorable regulatory environment, high R&D expenditure, and widespread outsourcing by pharmaceutical and biotechnology companies. Canada further contributes through expanding biomanufacturing infrastructure and government support for life sciences. Continuous investments in large-scale manufacturing facilities and increasing commercialization of biologics continue to strengthen North America's leadership position.

Asia-Pacific is projected to register the fastest growth during the forecast period due to rapidly expanding biopharmaceutical manufacturing capacity, increasing outsourcing from global pharmaceutical companies, and favorable government initiatives supporting biotechnology production. China, India, South Korea, and Singapore are emerging as major biomanufacturing hubs because of competitive manufacturing costs, skilled workforce, and significant investments in biologics, biosimilars, vaccines, and cell and gene therapies. Growing clinical research activities, increasing regulatory harmonization, and continuous expansion of GMP-certified manufacturing facilities are expected to further accelerate regional market growth throughout the forecast period.

Key Trends and Drivers

Growing Adoption of Integrated End-to-End CDMO Services:

Biopharmaceutical companies are increasingly partnering with contract manufacturing organizations that provide integrated services spanning cell line development, process optimization, clinical manufacturing, commercial-scale production, fill-finish, analytical testing, packaging, and regulatory support. This end-to-end outsourcing model reduces technology transfer risks, shortens development timelines, and improves manufacturing efficiency. Growing demand for biologics, biosimilars, antibody-drug conjugates (ADCs), and cell and gene therapies is encouraging CMOs to expand integrated service capabilities through capacity expansion, digital manufacturing platforms, and advanced bioprocessing technologies, enabling faster commercialization and greater supply chain flexibility.

Increasing Outsourcing of Biologics and Advanced Therapy Manufacturing:

The growth of the biopharmaceutical CMO market is primarily driven by increasing outsourcing of biologics, biosimilars, vaccines, and advanced therapies by pharmaceutical and biotechnology companies. Rising manufacturing complexity, high capital investment requirements, and stringent regulatory standards are encouraging drug developers to leverage specialized CMOs with advanced manufacturing expertise and GMP-certified facilities. Expanding biologics pipelines, increasing clinical trial activity, and growing demand for scalable commercial manufacturing are further accelerating outsourcing partnerships. Continuous investments in single-use bioprocessing, high-capacity manufacturing facilities, and specialized production technologies are expected to sustain strong market growth throughout the forecast period.

Research Scope

Estimates and forecasts the overall market size across type, application, and region.
Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

Product Code: GIS21593

1 Executive Summary

1.1 Market Size and Forecast
1.2 Market Overview
1.3 Market Snapshot
1.4 Regional Snapshot
1.5 Strategic Recommendations
1.6 Analyst Notes

2 Market Highlights

2.1 Key Market Highlights by Type
2.2 Key Market Highlights by Product
2.3 Key Market Highlights by Services
2.4 Key Market Highlights by Technology
2.5 Key Market Highlights by Application
2.6 Key Market Highlights by Process
2.7 Key Market Highlights by End User
2.8 Key Market Highlights by Stage

3 Market Dynamics

3.1 Macroeconomic Analysis
3.2 Market Trends
3.3 Market Drivers
3.4 Market Opportunities
3.5 Market Restraints
3.6 CAGR Growth Analysis
3.7 Impact Analysis
3.8 Emerging Markets
3.9 Technology Roadmap
3.10 Strategic Frameworks
- 3.10.1 PORTER's 5 Forces Model
- 3.10.2 ANSOFF Matrix
- 3.10.3 4P's Model
- 3.10.4 PESTEL Analysis

4 Segment Analysis

4.1 Market Size & Forecast by Type (2020-2035)
- 4.1.1 Mammalian
- 4.1.2 Microbial
- 4.1.3 Plant
- 4.1.4 Yeast
- 4.1.5 Insect
- 4.1.6 Others
4.2 Market Size & Forecast by Product (2020-2035)
- 4.2.1 Monoclonal Antibodies
- 4.2.2 Recombinant Proteins
- 4.2.3 Vaccines
- 4.2.4 Cell Therapy
- 4.2.5 Gene Therapy
- 4.2.6 Others
4.3 Market Size & Forecast by Services (2020-2035)
- 4.3.1 Process Development
- 4.3.2 Analytical and QC Studies
- 4.3.3 Packaging
- 4.3.4 Fill & Finish Operations
- 4.3.5 Others
4.4 Market Size & Forecast by Technology (2020-2035)
- 4.4.1 Single-Use Technology
- 4.4.2 Continuous Processing
- 4.4.3 Upstream Processing
- 4.4.4 Downstream Processing
- 4.4.5 Others
4.5 Market Size & Forecast by Application (2020-2035)
- 4.5.1 Oncology
- 4.5.2 Cardiovascular Diseases
- 4.5.3 Neurology
- 4.5.4 Infectious Diseases
- 4.5.5 Immunology
- 4.5.6 Others
4.6 Market Size & Forecast by Process (2020-2035)
- 4.6.1 Upstream
- 4.6.2 Downstream
- 4.6.3 Others
4.7 Market Size & Forecast by End User (2020-2035)
- 4.7.1 Pharmaceutical Companies
- 4.7.2 Biotechnology Companies
- 4.7.3 Research Organizations
- 4.7.4 Others
4.8 Market Size & Forecast by Stage (2020-2035)
- 4.8.1 Preclinical
- 4.8.2 Clinical
- 4.8.3 Commercial
- 4.8.4 Others

5 Regional Analysis

5.1 Global Market Overview
5.2 North America Market Size (2020-2035)
- 5.2.1 United States
  - 5.2.1.1 Type
  - 5.2.1.2 Product
  - 5.2.1.3 Services
  - 5.2.1.4 Technology
  - 5.2.1.5 Application
  - 5.2.1.6 Process
  - 5.2.1.7 End User
  - 5.2.1.8 Stage
- 5.2.2 Canada
  - 5.2.2.1 Type
  - 5.2.2.2 Product
  - 5.2.2.3 Services
  - 5.2.2.4 Technology
  - 5.2.2.5 Application
  - 5.2.2.6 Process
  - 5.2.2.7 End User
  - 5.2.2.8 Stage
- 5.2.3 Mexico
  - 5.2.3.1 Type
  - 5.2.3.2 Product
  - 5.2.3.3 Services
  - 5.2.3.4 Technology
  - 5.2.3.5 Application
  - 5.2.3.6 Process
  - 5.2.3.7 End User
  - 5.2.3.8 Stage
5.3 Latin America Market Size (2020-2035)
- 5.3.1 Brazil
  - 5.3.1.1 Type
  - 5.3.1.2 Product
  - 5.3.1.3 Services
  - 5.3.1.4 Technology
  - 5.3.1.5 Application
  - 5.3.1.6 Process
  - 5.3.1.7 End User
  - 5.3.1.8 Stage
- 5.3.2 Argentina
  - 5.3.2.1 Type
  - 5.3.2.2 Product
  - 5.3.2.3 Services
  - 5.3.2.4 Technology
  - 5.3.2.5 Application
  - 5.3.2.6 Process
  - 5.3.2.7 End User
  - 5.3.2.8 Stage
- 5.3.3 Rest of Latin America
  - 5.3.3.1 Type
  - 5.3.3.2 Product
  - 5.3.3.3 Services
  - 5.3.3.4 Technology
  - 5.3.3.5 Application
  - 5.3.3.6 Process
  - 5.3.3.7 End User
  - 5.3.3.8 Stage
5.4 Asia-Pacific Market Size (2020-2035)
- 5.4.1 China
  - 5.4.1.1 Type
  - 5.4.1.2 Product
  - 5.4.1.3 Services
  - 5.4.1.4 Technology
  - 5.4.1.5 Application
  - 5.4.1.6 Process
  - 5.4.1.7 End User
  - 5.4.1.8 Stage
- 5.4.2 India
  - 5.4.2.1 Type
  - 5.4.2.2 Product
  - 5.4.2.3 Services
  - 5.4.2.4 Technology
  - 5.4.2.5 Application
  - 5.4.2.6 Process
  - 5.4.2.7 End User
  - 5.4.2.8 Stage
- 5.4.3 South Korea
  - 5.4.3.1 Type
  - 5.4.3.2 Product
  - 5.4.3.3 Services
  - 5.4.3.4 Technology
  - 5.4.3.5 Application
  - 5.4.3.6 Process
  - 5.4.3.7 End User
  - 5.4.3.8 Stage
- 5.4.4 Japan
  - 5.4.4.1 Type
  - 5.4.4.2 Product
  - 5.4.4.3 Services
  - 5.4.4.4 Technology
  - 5.4.4.5 Application
  - 5.4.4.6 Process
  - 5.4.4.7 End User
  - 5.4.4.8 Stage
- 5.4.5 Australia
  - 5.4.5.1 Type
  - 5.4.5.2 Product
  - 5.4.5.3 Services
  - 5.4.5.4 Technology
  - 5.4.5.5 Application
  - 5.4.5.6 Process
  - 5.4.5.7 End User
  - 5.4.5.8 Stage
- 5.4.6 Taiwan
  - 5.4.6.1 Type
  - 5.4.6.2 Product
  - 5.4.6.3 Services
  - 5.4.6.4 Technology
  - 5.4.6.5 Application
  - 5.4.6.6 Process
  - 5.4.6.7 End User
  - 5.4.6.8 Stage
- 5.4.7 Rest of APAC
  - 5.4.7.1 Type
  - 5.4.7.2 Product
  - 5.4.7.3 Services
  - 5.4.7.4 Technology
  - 5.4.7.5 Application
  - 5.4.7.6 Process
  - 5.4.7.7 End User
  - 5.4.7.8 Stage
5.5 Europe Market Size (2020-2035)
- 5.5.1 Germany
  - 5.5.1.1 Type
  - 5.5.1.2 Product
  - 5.5.1.3 Services
  - 5.5.1.4 Technology
  - 5.5.1.5 Application
  - 5.5.1.6 Process
  - 5.5.1.7 End User
  - 5.5.1.8 Stage
- 5.5.2 France
  - 5.5.2.1 Type
  - 5.5.2.2 Product
  - 5.5.2.3 Services
  - 5.5.2.4 Technology
  - 5.5.2.5 Application
  - 5.5.2.6 Process
  - 5.5.2.7 End User
  - 5.5.2.8 Stage
- 5.5.3 United Kingdom
  - 5.5.3.1 Type
  - 5.5.3.2 Product
  - 5.5.3.3 Services
  - 5.5.3.4 Technology
  - 5.5.3.5 Application
  - 5.5.3.6 Process
  - 5.5.3.7 End User
  - 5.5.3.8 Stage
- 5.5.4 Spain
  - 5.5.4.1 Type
  - 5.5.4.2 Product
  - 5.5.4.3 Services
  - 5.5.4.4 Technology
  - 5.5.4.5 Application
  - 5.5.4.6 Process
  - 5.5.4.7 End User
  - 5.5.4.8 Stage
- 5.5.5 Italy
  - 5.5.5.1 Type
  - 5.5.5.2 Product
  - 5.5.5.3 Services
  - 5.5.5.4 Technology
  - 5.5.5.5 Application
  - 5.5.5.6 Process
  - 5.5.5.7 End User
  - 5.5.5.8 Stage
- 5.5.6 Rest of Europe
  - 5.5.6.1 Type
  - 5.5.6.2 Product
  - 5.5.6.3 Services
  - 5.5.6.4 Technology
  - 5.5.6.5 Application
  - 5.5.6.6 Process
  - 5.5.6.7 End User
  - 5.5.6.8 Stage
5.6 Middle East & Africa Market Size (2020-2035)
- 5.6.1 Saudi Arabia
  - 5.6.1.1 Type
  - 5.6.1.2 Product
  - 5.6.1.3 Services
  - 5.6.1.4 Technology
  - 5.6.1.5 Application
  - 5.6.1.6 Process
  - 5.6.1.7 End User
  - 5.6.1.8 Stage
- 5.6.2 United Arab Emirates
  - 5.6.2.1 Type
  - 5.6.2.2 Product
  - 5.6.2.3 Services
  - 5.6.2.4 Technology
  - 5.6.2.5 Application
  - 5.6.2.6 Process
  - 5.6.2.7 End User
  - 5.6.2.8 Stage
- 5.6.3 South Africa
  - 5.6.3.1 Type
  - 5.6.3.2 Product
  - 5.6.3.3 Services
  - 5.6.3.4 Technology
  - 5.6.3.5 Application
  - 5.6.3.6 Process
  - 5.6.3.7 End User
  - 5.6.3.8 Stage
- 5.6.4 Sub-Saharan Africa
  - 5.6.4.1 Type
  - 5.6.4.2 Product
  - 5.6.4.3 Services
  - 5.6.4.4 Technology
  - 5.6.4.5 Application
  - 5.6.4.6 Process
  - 5.6.4.7 End User
  - 5.6.4.8 Stage
- 5.6.5 Rest of MEA
  - 5.6.5.1 Type
  - 5.6.5.2 Product
  - 5.6.5.3 Services
  - 5.6.5.4 Technology
  - 5.6.5.5 Application
  - 5.6.5.6 Process
  - 5.6.5.7 End User
  - 5.6.5.8 Stage

6 Market Strategy

6.1 Demand-Supply Gap Analysis
6.2 Trade & Logistics Constraints
6.3 Price-Cost-Margin Trends
6.4 Market Penetration
6.5 Consumer Analysis
6.6 Regulatory Snapshot

7 Competitive Intelligence

7.1 Market Positioning
7.2 Market Share
7.3 Competition Benchmarking
7.4 Top Company Strategies

8 Company Profiles

8.1 Lonza
- 8.1.1 Overview
- 8.1.2 Product Summary
- 8.1.3 Financial Performance
- 8.1.4 SWOT Analysis
8.2 Samsung Biologics
- 8.2.1 Overview
- 8.2.2 Product Summary
- 8.2.3 Financial Performance
- 8.2.4 SWOT Analysis
8.3 Catalent
- 8.3.1 Overview
- 8.3.2 Product Summary
- 8.3.3 Financial Performance
- 8.3.4 SWOT Analysis
8.4 Boehringer Ingelheim
- 8.4.1 Overview
- 8.4.2 Product Summary
- 8.4.3 Financial Performance
- 8.4.4 SWOT Analysis
8.5 WuXi Biologics
- 8.5.1 Overview
- 8.5.2 Product Summary
- 8.5.3 Financial Performance
- 8.5.4 SWOT Analysis
8.6 Thermo Fisher Scientific
- 8.6.1 Overview
- 8.6.2 Product Summary
- 8.6.3 Financial Performance
- 8.6.4 SWOT Analysis
8.7 Fujifilm Diosynth Biotechnologies
- 8.7.1 Overview
- 8.7.2 Product Summary
- 8.7.3 Financial Performance
- 8.7.4 SWOT Analysis
8.8 Siegfried Holding
- 8.8.1 Overview
- 8.8.2 Product Summary
- 8.8.3 Financial Performance
- 8.8.4 SWOT Analysis
8.9 Recipharm
- 8.9.1 Overview
- 8.9.2 Product Summary
- 8.9.3 Financial Performance
- 8.9.4 SWOT Analysis
8.10 AGC Biologics
- 8.10.1 Overview
- 8.10.2 Product Summary
- 8.10.3 Financial Performance
- 8.10.4 SWOT Analysis
8.11 Jubilant Biosys
- 8.11.1 Overview
- 8.11.2 Product Summary
- 8.11.3 Financial Performance
- 8.11.4 SWOT Analysis
8.12 Rentschler Biopharma
- 8.12.1 Overview
- 8.12.2 Product Summary
- 8.12.3 Financial Performance
- 8.12.4 SWOT Analysis
8.13 Patheon
- 8.13.1 Overview
- 8.13.2 Product Summary
- 8.13.3 Financial Performance
- 8.13.4 SWOT Analysis
8.14 Baxter BioPharma Solutions
- 8.14.1 Overview
- 8.14.2 Product Summary
- 8.14.3 Financial Performance
- 8.14.4 SWOT Analysis
8.15 Cytiva
- 8.15.1 Overview
- 8.15.2 Product Summary
- 8.15.3 Financial Performance
- 8.15.4 SWOT Analysis
8.16 KBI Biopharma
- 8.16.1 Overview
- 8.16.2 Product Summary
- 8.16.3 Financial Performance
- 8.16.4 SWOT Analysis
8.17 AbbVie Contract Manufacturing
- 8.17.1 Overview
- 8.17.2 Product Summary
- 8.17.3 Financial Performance
- 8.17.4 SWOT Analysis
8.18 Ajinomoto Bio-Pharma Services
- 8.18.1 Overview
- 8.18.2 Product Summary
- 8.18.3 Financial Performance
- 8.18.4 SWOT Analysis
8.19 Alcami
- 8.19.1 Overview
- 8.19.2 Product Summary
- 8.19.3 Financial Performance
- 8.19.4 SWOT Analysis
8.20 CordenPharma
- 8.20.1 Overview
- 8.20.2 Product Summary
- 8.20.3 Financial Performance
- 8.20.4 SWOT Analysis

9 About Us

9.1 About Us
9.2 Research Methodology
9.3 Research Workflow
9.4 Consulting Services
9.5 Our Clients
9.6 Client Testimonials
9.7 Contact Us